VBI Vaccines, Inc. – (NASDAQ:VBIV) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 788,524 shares, a growth of 51.2% from the February 15th total of 521,575 shares. Based on an average daily volume of 147,408 shares, the days-to-cover ratio is currently 5.3 days. Approximately 6.6% of the shares of the company are sold short.
Several research firms recently issued reports on VBIV. Zacks Investment Research lowered shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd. BidaskClub lowered shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research report on Saturday, January 20th. Finally, BMO Capital Markets began coverage on shares of VBI Vaccines in a research report on Wednesday, November 15th. They set an “outperform” rating and a $11.00 price target on the stock. Three analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $8.75.
Shares of VBI Vaccines (NASDAQ VBIV) opened at $4.06 on Tuesday. The company has a current ratio of 5.32, a quick ratio of 5.26 and a debt-to-equity ratio of 0.10. VBI Vaccines has a 52-week low of $3.04 and a 52-week high of $6.60.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.